LATEST NEWS
ImmunoVaccine Technologies’ DepoVax™ Shows Positive Results for Cancer and Infectious Diseases
October 1, 2008
More Information
ImmunoVaccine Technologies selected as Canada's Top 10™ Life Sciences Companies
September 30, 2008
More Information
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
August 5, 2008
More Information
Warwick Kimmins Science Scholarship Awarded
June 26, 2008
More Information
International Convention to Showcase Atlantic Canada's Contributions to Biotechnology Innovation
June 16, 2008
More Information
Bioject and ImmunoVaccine Technologies Announce Research Collaboration
June 5, 2008
More Information
ImmunoVaccine Technologies Unveils Warwick Kimmins Science Scholarship
June 2, 2008
More Information
ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PA's Best 50 Women in Business
May 23, 2008
More Information
IVT patents DepoVax vaccine delivery system
May 12, 2008
Related Link: http://www.pharmaceutical-business-review.com/article_news.asp?guid=06F8F9AA-FE30-4102-AB08-F0B2F9995C2D
ImmunoVaccine Technologies Patents DepoVax™ Vaccine Platform
April 30, 2008
More Information
Interview with Dr. Randal Chase, CEO of ImmunoVaccine Technologies
April 29, 2008
Related Link: http://www.onemedplace.com/blog/archives/664
Source:
ImmunoVaccine Technologies Appoints The Honourable Michael Kirby as Chair
February 20, 2008
More Information
ImmunoVaccine Technologies Discusses Phase I Clinical Trial Application
January 23, 2008
More Information
Funding boost for innovative VacciMax platform
January 22, 2008
Related Link: http://www.in-pharmatechnologist.com/news/ng.asp?n=82696&m=1ipe122&c=imofrcahcaosyol
ImmunoVaccine Technologies Receives $3 Million from ACOA
January 21, 2008
More Information
ImmunoVaccine Technologies licenses the VacciMax® platform to Pfizer Animal Health for future animal vaccine applications
January 14, 2008
More Information
ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.
December 10, 2007
More Information
IVT Wins Innovation Award
December 3, 2007
More Information
ImmunoVaccine Technologies Inc. Completes Scale-Up of VacciMax® to Commercially Relevant Scale
November 29, 2007
More Information
ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
September 27, 2007
More Information
ImmunoVaccine Technologies Inc. Scientific Advisory Board Welcomes New Members
May 31, 2007
More Information
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®
April 23, 2007
More Information
IVT receives Innovation Award at Discovery Awards banquet
January 12, 2007
IVT was presented with an Innovation Award for Outstanding Achievement in the field of Science and Technology from the Discovery Awards for Science & Technology, a project of Discovery Centre. Dr. Pirouz Daftarian, Head Scientist, Cancer Research, accepted the award on behalf of IVT on November 30, 2006 at a ceremony held at The Westin Hotel located in Halifax, Nova Scotia.
IVT receives 2006 NRC-IRAP Regional Awards for New Technology
January 12, 2007
IVT was presented with the 2006 NRC-IRAP Regional Awards for New Technology as the Atlantic/Nunavut Finalist.
IVT announces addition of Dr. Randal Chase as President & CEO
December 1, 2006
Related Link: senior-management.php
Premier MacDonald to Proclaim Biotechnology and Life Sciences Week in Nova Scotia
September 20, 2006
More Information
IVT announces addition of Mr. Ron Smith as Chief Financial Officer
September 13, 2006
Related Link: senior-management.php#RS
Pharmexa grants PADRE® license to ImmunoVaccine Technologies Inc.
August 31, 2006
More Information
IVT Therapeutic Cancer Vaccine Workshop being held October 19th & 20th, 2006
August 31, 2006
Dalhousie receives cash dividend from spin off company ImmunoVaccine Technologies Inc.
August 29, 2006
More Information
Recent IVT publication selected by "LeadDiscovery" as a groundbreaking cancer immunotherapy
May 16, 2006
More Information
Results of the therapeutic effects of VacciMax® on HPV-bearing tumors published in the journal
April 18, 2006
More Information
Dr. Michel Klein, IVT Scientific Advisor, receives prestigious award.
March 3, 2006
Related Link: press-releases.php
Knight who Fights Disease Among Those Given SCI Awards
March 1, 2006
More Information
IVT announces addition of Mr. Ron Smith and Mr. Wade Dawe to the Board of Directors.
December 9, 2005
Related Link: board-of-directors.php
Vaccine Development Company Receives European Patent Allowance
September 26, 2005
More Information
IVT announces addition of Dr. Michel Klein to the Scientific Advisory Board.
August 4, 2005
Related Link: technical-advisors.php
ImmunoVaccine Technologies Earns National Recognition
May 30, 2005
For more information: InnovaCorp Client News June 2005 .pdf
Related Link: http://www.innovacorp.ns.ca/clients
Dr. Marc Mansour, Head Scientist, Reproductive Biology and Head Scientist, Infectious Diseases
March 24, 2004
HALIFAX, Nova Scotia, (March 21, 2004) Dr. Warwick Kimmins, President and CEO of ImmunoVaccine Technologies Inc. (IVT), is pleased to announce the appointment of Dr. Marc Mansour as Head Scientist, Reproductive Biology and Head Scientist, Infectious Diseases. Dr. Mansour received his doctorate from Dalhousie University in 2001. His expertise lies in the field of molecular biology and immunology. His previous work included the generation of transgenic fish for human medical applications and the structural/ functional characterization of numerous genes expressed in specialized cells of the human immune system. Since he graduated, Dr. Mansour has been working at ImmunoVaccine Technologies in the capacity of research scientist in the R&D division. Dr. Mansour's recent contributions at ImmunoVaccine Technologies include the functional characterization and tailoring of the VacciMax® platform for a variety of contraceptive and infectious disease vaccines. The appointment of Dr. Mansour as head scientist is a reflection of the recent advancement achieved in the development of preclinical vaccine candidates entering ImmunoVaccine Technologies' product pipeline.
About IVT IVT is a vaccine enhancement company with a unique platform technology, VacciMax®, which can be applied to most human and veterinary vaccines and immunotherapies. In addition to its current veterinary projects, other IVT programs include industry relationships to develop human vaccines against infectious disease and cancer. The VacciMax® vaccine enhancement technology was originally developed at Dalhousie University, Halifax, Nova Scotia. ImmunoVaccine Technologies is seeking other agreements for vaccine product development with industry partners.
BIOTECanada Award
More Information
Dr. Pirouz Daftarian, Head Scientist, Tumour Biology
September 2004
Dr. Warwick Kimmins, President and CEO of ImmunoVaccine Technologies Inc. (IVT), is pleased to announce the appointment of Dr. Pirouz Daftarian as Head Scientist, Tumour Biology.
Dr. Pirouz Daftarian has been appointed effective July 1, 2004. Dr. Daftarian was our 1st ranked candidate from 256 applications, and joins us from the Beckman Institute in California. IVT appreciates the assistance provided by ACOA under the Innovative Skills Development Initiative (ISDI) Program which provided support for Dr. Daftarian’s relocation expenses and salary in the form of a non-repayable grant.
Dr. Daftarian received his Ph.D. degree from the University of Ottawa in 1997. He did his fellowship in Immunology/virology and Cancer at the Childrens Hospital, University of Ottawa and BC Children’s Hospital of UBC. In April 2002, Dr. Daftarian began working at the Laboratory for Vaccine Research in the Beckman Research Institute of The City of Hope, Duarte, California. Dr. Daftarian has presented internationally on vaccine and immunology meetings. He has also published in peer reviewed manuscripts, and abstracts in scientific journals in the area of vaccines for Cancer, CMV and HIV as well as HIV immunopathogenesis.
ImmunoVaccine Technologies Inc. is a Halifax biotechnology company providing a unique liposome-based single-dose vaccine platform, trade-named VacciMax® to companies seeking to develop enhanced-response vaccines. IVT’s first products are immunocontraceptive vaccines for controlling animal fertility, under the trade-name SpayVac®. IVT is currently expanding its vaccine program for the therapeutic treatment of several human cancers.
IVT receives patent allowance from European patent office.
2005-09-26 Related Link: press-releases.php
